Summit Therapeutics Inc.
(NASDAQ:SMMT) on Wednesday shared updated overall survival (OS) data from its Phase 3 HARMONi study, evaluating the investigational bispecific antibody ivonescimab for treating specific forms of lung cancer.
The study is evaluating ivonescimab combined with chemotherapy compared to placebo plus chemotherapy for endothelial growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who were previously treated with a third-generation EGFR tyrosine kinase inhibitor (TKI).
Read Also: Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst The latest analysis continues to demonstrate a favorable overall survival trend and a consistent safety profile across diverse patient populations.
Prolonged Follow-Up Enhances Efficacy Trends The HARMONi trial investigates ivonescimab paired with chemotherapy against a placebo and chemotherapy regimen.
